MHRA publishes September 2026 performance data against key performance indicators
The latest monthly release adds to a series of transparency data on the agency's KPIs and expected timelines for specific regulatory functions, running since March 2025.
The Medicines and Healthcare products Regulatory Agency (MHRA) added 'MHRA Performance Data - September 2026' to its transparency data page on 27 October 2026. The page covers performance against the agency's key performance indicators (KPIs) and gives information on the expected timeline for completing specific regulatory functions.
The page was first published on 27 March 2025. Its update log shows a release roughly every month since then, with each entry covering the previous month. The September 2026 release follows August 2026 data, published on 23 September, and July 2026 data, published on 27 August.
The log also records an update on 28 April 2026 described as 'Updated performance data for March 2024'. The year is given as stated in the source and is out of sequence with the surrounding entries. The source does not explain the entry.
The source text gives no figures, so this report cannot say how the agency performed against any indicator or whether processing times have moved. The MHRA describes predictable, high-quality services as central to its Strategy to 2030, and says the KPIs are meant to provide transparency and clarity on its performance.
What it means for your team
- Check the full September 2026 document on GOV.UK for current MHRA performance figures and expected timelines before fixing UK submission plans.
- The monthly cadence lets teams track trends over time. Compare several months rather than relying on a single release.
- The source gives no numbers or commentary on changes, so any conclusions about processing times should come from the data itself.
Article written by VigiEye from the official source (MHRA). AI-assisted; check the source before acting.
RegulatoryCompany releaseBeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
RegulatoryCompany releaseImricor starts US launch of NorthStar iMR system after paediatric FDA clearances
RegulatoryCompany releaseBeyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
RegulatoryCompany releaseFDA sets 10 March 2027 goal date for Intellia's one-time hereditary angioedema gene-editing therapy
RegulatoryCompany releaseBeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
RegulatoryCompany release